Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker (dihydropyridine) presented as an injectable solution for intravenous use. It is employed to prevent cerebral vasospasm following subarachnoid hemorrhage, improving cerebral blood flow in affected patients.

GNH USA supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with full regulatory compliance and quality assurance. Our distribution network ensures timely delivery across multiple regions.

Nimodipine is a calcium channel blocker used in the management of cerebrovascular complications.

- Subarachnoid hemorrhage: prevention of cerebral vasospasm to reduce delayed ischemic neurological deficits. - Aneurysmal rupture recovery: management of delayed cerebral ischemia by maintaining arterial patency. - Neurocritical care: support of cerebral perfusion in patients at risk of vasospasm.

Nimodipine may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient drop in blood pressure. - Nausea: occasional gastrointestinal upset. - Flushing: warmth and redness of skin. - Dizziness: sensation of light‑headedness. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: profound blood pressure reduction requiring intervention. - Myocardial infarction: rare cardiac ischemic events. - Bradycardia: markedly slow heart rate. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, pruritus, or anaphylaxis. - Seizures: infrequent neurologic events.

When using Nimotop, clinicians should observe several precautionary measures to ensure patient safety.

- Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: use with caution; monitor liver enzymes. - Hypotension: observe blood pressure regularly during infusion. - Concomitant vasodilators: avoid additive hypotensive effects. - Pregnancy: safety not established; avoid unless benefits outweigh risks. - Store at ambient temperature: keep in original container, protect from light and moisture.

Nimodipine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Other potent vasodilators (e.g., nitroglycerin): risk of severe hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase plasma concentrations. - Combined use with beta‑blockers: may exacerbate bradycardia.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - Diuretics: may enhance hypotensive response. - Anticoagulants: monitor for bleeding if hypotension occurs.